Christian Manegold Nick Thatcher Christian Manegold, Heidelberg University Medical Center, Manheim Nick Thatcher, Christie Hospital, Manchester Is bevacizumab a new standard of care for patients with
Christian Manegold
Nick ThatcherChristian Manegold, Heidelberg University Medical Center, ManheimNick Thatcher, Christie Hospital, Manchester
Is bevacizumab a new standard of care for patients with unresectable non-small cell lung cancer who have good performance status? This question was raised in a debate at the European Congress on Lung Cancer held in Turin.Christian Manegoldprovided delegates with evidence from the AVAil and ECOG 4599 studies which underpin current approval of this anti-vascular endothelial growth factor (VEG-F) antibody.Nick Thatcherpointed out the limitations. They both talked with Peter Goodwin.
Related Episodes
Hassan Mohammed Abushukair MD; AACR 2026: Immune Checkpoint Inhibitor-Induced Myocarditis within One Month Predicts Lethal “Triple M Overlap Syndrome”
Immune Checkpoint Inhibitor-Induced Myocarditis within One Month Predicts Lethal “Triple M Overlap Syndrome” An interview with: Hassan Mohammed Abushukair MD, Post-Doctoral Researcher, Oklahoma Univer
Aditya Bardia MD MPH; 2025 San Antonio Breast Cancer Symposium: Selective Estrogen Degrader Giredestrant Improves on Standard Endocrine Therapy for Patients with ER-positive, HER2-negative Early Breast Cancer: Phase III lidERA Breast Cancer trial Findings
A seective estrogen degrader out-performed AI’s in ER+ HER- early breast cancer
Li Zhang MD; ESMO 2025: Patients with EGFR-mutated Lung Cancer Progressing After Tyrosine Kinase Therapy Live Longer with Sacituzumab Tirumotecan Therapy
Antibody Drug Conjugate Prolongs Life in NSCLC refractory to EGFR TKI Therapy